Compositions and methods for protein detection
AssigneeSyngenta Participations AG
InventorsSimone Cummings, Julie Smith, Magda Foege
Life of this patent
Estimating the term…
Abstract
The invention relates generally to immunoassays, and more particularly to monoclonal antibodies and immunoassays for the differential detection and quantitation of a wild-type crystal protein, such as a wild-type-Cry1Ab, from Bacillus thuringiensis and hybrid crystal proteins, which comprise all or a significant portion of the wild-type Cry protein in complex biological samples comprising both the wild-type Cry protein and one or more of the hybrid Cry proteins.
Claims14
A composition comprising a first monoclonal 87AB1.1 antibody and a second monoclonal H04MAb70 antibody produced by a hybridoma cell line deposited as ATCC Accession No. PTA-122984 that function together to specifically detect or quantitate a Cry1Ab protein comprising SEQ ID NO:1 in an immunoassay of a biological sample comprising the Cry1Ab protein and a hybrid Cry protein comprising SEQ ID NO:3, wherein the first antibody and the second antibody individually are capable of binding to both the Cry1Ab protein and the hybrid Cry protein but that function together in the immunoassay to specifically detect or quantitate the Cry1Ab protein and not the hybrid Cry protein.
A monoclonal antibody produced by a hybridoma deposited as ATCC Accession No. PTA-122984.
The monoclonal antibody of 13 that is H04Mab70 antibody.
An immunoassay method to detect or quantitate a Cry1Ab protein comprising SEQ ID NO:1 and a hybrid Cry protein comprising SEQ ID NO:3 in a biological sample from a transgenic corn plant comprising the Cry1Ab protein and the hybrid Cry protein, the method comprising (a) coating a first solid surface with a first antibody that is 87AB1.1 that binds the Cry1Ab protein but does not bind the hybrid Cry protein and coating a second solid surface with a second antibody that is MAb58 produced by a hybridoma cell line deposited as ATCC Accession No. PTA-122985 that binds the hybrid Cry protein;
- (b) contacting the biological sample with the 87AB1.1 antibody under conditions effective to allow the formation of a Cry1Ab-87AB1.1 antibody complex but does not allow the formation of a hybrid Cry protein-87AB1.1 antibody complex, resulting in a Cry1Ab-depleted biological sample;
- (c) removing the Cry1Ab-depleted biological sample and contacting the Cry1Ab-depleted biological sample with the MAb58 antibody under conditions effective to allow the formation of a hybrid Cry protein-MAb58 antibody complex;
- (d) detecting or quantitating the Cry1Ab protein complex on the first solid surface;
- and (e) detecting or quantitating the hybrid Cry protein on the second solid surface.
Dependencies are inferred from the claim text.